Durata Therapeutics to Present at Credit Suisse 2012 Healthcare Conference
Durata Therapeutics to Present at Credit Suisse 2012 Healthcare Conference
MORRISTOWN, N.J.--(BUSINESS WIRE)-- Durata Therapeutics (NAS: DRTX) today announced that Durata Chief Executive Officer Paul R. Edick will present an overview of the company at the Credit Suisse Healthcare Conference. The Durata presentation will take place at The Arizona Biltmore, Phoenix, Arizona on Thursday, November 15, 2012 at 3:00 p.m. MST.
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed enrollment in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with ABSSSI.
Forward-looking statements
Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
Investor Relations and Public Affairs Contact
Durata Therapeutics
Allison Wey
Vice President, Investor Relations and Public Affairs
(312) 612-5462
awey@duratatherapeutics.com
or
Media Relations Contact
White Oak Communications, Inc.
Jed Weiner
(847) 392-4186
jed.weiner@comcast.net
KEYWORDS: United States North America Arizona New Jersey
INDUSTRY KEYWORDS:
The article Durata Therapeutics to Present at Credit Suisse 2012 Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
